15 research outputs found
Dose response curves for cenicriviroc-dependent inhibition (A) and maraviroc-dependent inhibition (B).
<p>R5, dual and X4-tropic HIV-2 strains are depicted in continuous, dashed and dotted black lines, respectively. HIV-1 R5-tropic strain is depicted using the continuous gray line.</p
Characteristics of HIV/HCV co-infected patients (<i>n</i> = 60).
<p>Continuous variables were expressed as medians and interquartile ranges (IQR), and categorical variables were expressed as numbers and percentages.</p><p>ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma glutamyl transpeptidase.</p
Factors associated with the METAVIR liver fibrosis stage.
<p>Continuous variables were expressed as median and interquartile range (IQR).</p><p>ALT: alanine aminotransferase; aOR: adjusted odds ratio; AST: aspartate aminotransferase; OR [CI95%]: odds ratio and 95% confidence interval.</p
Correlation between FibroScan® values and inflammatory biomarkers (Spearman rank’s test).
<p>Correlation between FibroScan® values and inflammatory biomarkers (Spearman rank’s test).</p
Proportion of protease inhibitors resistance-associated mutations with the L76V mutation in HIV-1 subtype B samples and in HIV-1 “non-B” samples.
<p>P-values are indicated only if significant.</p
Longitudinal follow-up of HIV-1 DNA level during the ANRS 139 TRIO Trial.
<p>Longitudinal follow-up of HIV-1 DNA level during the ANRS 139 TRIO Trial.</p
Prevalence of the L76V mutation between 1998 and 2010 in a database containing 29,643 sequences issued from clinical samples with any antiretroviral drug resistance.
<p>Prevalence of the L76V mutation between 1998 and 2010 in a database containing 29,643 sequences issued from clinical samples with any antiretroviral drug resistance.</p
Population characteristics of patients infected with HIV-1 subtype B and HIV-1 “non-B” subtypes with L76V protease mutation.
*<p>Continuous variables were expressed as median and interquartile range (IQR) and categorical variables were expressed as numbers and percentages.</p><p>95% CI: 95% Confidence Interval; ARV: antiretroviral; PI: protease inhibitor.</p
Dendrograms obtained from average linkage hierarchical agglomerative clustering, showing significant clusters of L76V protease inhibitors resistance mutations among B subtype sequences (A), and among “non-B” subtype sequences (B).
<p>The length of branches reflects distances between mutations in the original distance matrix. Bootstrap values, indicating the significance of clusters, are reported in the boxes.</p
Twelve Months of Routine HIV Screening in 6 Emergency Departments in the Paris Area: Results from the ANRS URDEP Study
<div><h3>Objective</h3><p>In October 2009 the French National Authority for Health recommended that HIV testing be proposed at least once to all persons aged 15 to 70 years in all healthcare settings. We examined whether routine HIV screening with a rapid test in emergency departments (EDs) was feasible without dedicated staff, and whether newly diagnosed persons could be linked to care.</p> <h3>Methods</h3><p>This one-year study started in December 2009 in 6 EDs in the Paris area, using the INSTI™ test. Eligible individuals were persons 18 to 70 years old who did not present for a vital emergency, for blood or sexual HIV exposure, or for HIV screening. Written informed consent was required.</p> <h3>Results</h3><p>Among 183 957 eligible persons, 11 401 were offered HIV testing (6.2%), of whom 7936 accepted (69.6%) and 7215 (90.9%) were tested (overall screening rate 3.9%); 1857 non eligible persons were also tested. Fifty-five new diagnoses of HIV infection were confirmed by Western blot (0.61% (95% CI 0.46–0.79). There was one false-positive rapid test result. Among the newly diagnosed persons, 48 (87%) were linked to care, of whom 36 were not lost to follow-up at month 6 (75%); median CD4 cell count was 241/mm<sup>3</sup> (IQR: 52–423/mm<sup>3</sup>).</p> <h3>Conclusions</h3><p>Screening rates were similar to those reported in opt-in studies with no dedicated staff. The rate of new diagnoses was similar to that observed in free anonymous test centres in the Paris area, and well above the prevalence (0.1%) at which testing has been shown to be cost-effective.</p> </div